Question
Read the clinical problem and answer the following questions:
(a) After injection of succinylcholine i.v. to provide muscle relaxation, the patient developed 2 mark(s)
(b) What is the probable reason for this. 2 mark(s)
(c) Can edrophonium be given as antidote. If yes, why and if not why not. 2 mark(s)
(d) What is the line of treatment.
Q2 6 marks Essays ★ ✓
Answer
(a) What the patient developed
Prolonged apnoea/sustained neuromuscular paralysis (“scoline apnoea”) following the standard dose of succinylcholine
(b) Probable reason
Succinylcholine is normally rapidly hydrolysed by plasma pseudocholinesterase (butyrylcholinesterase), giving it a very short duration of action
Some individuals have a genetically determined atypical or deficient form of plasma pseudocholinesterase (autosomal recessive trait), which hydrolyses succinylcholine very slowly
In such patients, the depolarizing neuromuscular block is grossly prolonged, causing sustained paralysis of the respiratory muscles and prolonged apnoea
(c) Can edrophonium be given as an antidote?
No. Succinylcholine produces a depolarizing (Phase I) neuromuscular block. Anticholinesterases like edrophonium increase acetylcholine at the neuromuscular junction, which would further prolong/worsen a depolarizing block rather than reverse it (anticholinesterases only reverse non-depolarizing/competitive blockade)
(d) Line of treatment
Continue mechanical ventilation/assisted respiration and maintain sedation/anaesthesia until neuromuscular function recovers spontaneously
Do NOT give further muscle relaxants or anticholinesterases
Confirm diagnosis with a dibucaine number test and counsel the patient/family regarding the genetic trait for future anaesthetic exposures
Fresh frozen plasma (source of normal pseudocholinesterase) may be considered in severe/prolonged cases
1 Cholinergic System
Other Years Asked
1 ( 2024 March (Supplementary) (2019 Scheme) Short Essay · 8 marks 2 ( 2023 July (Supplementary) (2019 Scheme) Short Essay · 8 marks 3 A man aged 45 years presented with complaints of gradual onset double vision,
drooping eyelids, difficulty in chewing food and weakness of limbs which is accentuated
by exercise. The symptoms fluctuate in intensity over time. A provisional diagnosis of
Myasthenia gravis is made. 2025 March (Supplementary) (2010 Scheme) Essay · 6 marks 4 Enumerate the topical group of agents used in the treatment of open angle glaucoma.
Give examples and explain the mechanism of action of each group of drugs. (2+2+2) 2019 February (2010 Scheme) Essay · 6 marks 5 min. He gives history of spraying a strong insecticide in his
agricultural field.
( 2023 March (Supplementary) (2010 Scheme) Essay · 6 marks 6 A 22-year-old farmer was brought to the casualty with symptoms of nausea, vomiting,
severe abdominal pain, lacrimation, salivation, blurring of vision, muscular twitches and
weakness. He was suspected to have consumed Organo-phosphorous compound. 2024 March (Supplementary) (2010 Scheme) Essay · 6 marks 7 Classify anticholinergic drugs. Describe the pharmacological actions, therapeutic
uses and contraindications of atropine. (2+2+1+1) 2021 February (Supplementary) (2010 Scheme) Essay · 6 marks 8 Classify atropine substitutes, explain their uses and adverse effects (3+2+1) 2022 May (Supplementary) (2010 Scheme) Essay · 6 marks 9 A patient suffering from schizophrenia was being treated with haloperidol for the last four
weeks. Now he developed rigidity, tremors, hypokinesia and classical gait. Answer the
following: 2017 February (2010 Scheme) Essay · 6 marks 10 What is the rationale of using Beta-blockers in Glaucoma. 2023 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 11 Therapeutic uses and adverse effects of Neostigmine 2022 February (2019 Scheme) Short Answer · 4 marks 12 Pharmacotherapy of Organophosphorous poisoning 2022 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 13 Pharmacological basis for the use of Timolol in glaucoma. 2024 June (Supplementary) (2019 Scheme) Short Answer · 4 marks 14 Pharmacological management of Myasthenia gravis. 2022 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 15 Treatment of organophosphorus poisoning 2013 September (Supplementary) (2010 Scheme) Short Note · 3 marks 16 Drug treatment of anti cholinesterase poisoning 2013 April (2010 Scheme) Short Note · 3 marks 17 Neostigmine 2021 December (Supplementary) (2010 Scheme) Short Note · 3 marks 18 Treatment of organophosphorous poisoning 2014 September (Supplementary) (2010 Scheme) Short Note · 3 marks 19 Atropine 2015 February (2010 Scheme) Short Note · 3 marks 20 Therapeutic uses and adverse effects of atropine. 2016 October (Supplementary) (2010 Scheme) Short Note · 3 marks 21 Neostigmine. 2017 August (Supplementary) (2010 Scheme) Short Note · 3 marks 22 Edrophonium 2018 February (2010 Scheme) Short Note · 3 marks 23 Pralidoxime in organophosphate compound poisoning 2021 December (Supplementary) (2010 Scheme) Short Answer · 1 mark 24 Toxicities of atropine include the following:
1. Bradycardia 2. Dry mouth 3. Miosis 4. Psychotic behavior 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 25 Assertion (A): Neostigmine and its congeners are the first line drugs used to restore muscle
strength in myasthenia gravis.
Reason (R): They improve muscle contraction by allowing acetylcholine released from
prejunctional endings to accumulate and act on the nicotinic receptors over a wider area. 2024 December (Supplementary) (2019 Scheme) MCQ · 1 mark 26 The drug that should be used cautiously in Mrs. Rose, who has a history of bronchial asthma 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ (Case) · 1 mark 27 Explain briefly why physostigmine is preferred over neostigmine for the treatment of glaucoma. 2015 February (2010 Scheme) Short Answer · 1 mark 28 Anti- muscarinic drugs 2017 August (Supplementary) (2010 Scheme) Short Answer · 1 mark 29 Drugs used in myasthenia gravis. 2016 October (Supplementary) (2010 Scheme) Short Answer · 1 mark 30 Assertion (A): Pralidoxime is most specific drug for organophosphate poisoning.
Reason (R): Organophosphates block AChE enzyme 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ (A/R) · 1 mark 31 Management of organophosphorus poisoning. 2016 February (2010 Scheme) Short Answer · 1 mark 32 Trihexyphenidyl in the treatment of Drug induced parkinsonism 2024 August (Supplementary) (2010 Scheme) Short Answer · 1 mark 33 Explain the rationale for the use of oximes in organophosphorus poisoning. 2017 August (Supplementary) (2010 Scheme) Short Answer · 1 mark 34 Rationale for use of pilocarpine in glaucoma 2018 July (Supplementary) (2010 Scheme) Short Answer · 1 mark 35 Two uses and two adverse effects of atropine 2014 March (2010 Scheme) Short Answer · 1 mark 36 Rationale for use of physostigmine in atropine poisoning 2015 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 37 Rationale for the use of glycopyrrolate in pre-anesthetic medication. 2016 October (Supplementary) (2010 Scheme) Short Answer · 1 mark 38 Cholinesterase reactivators 2015 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 39 Atropine as antisecretory agent 2019 February (2010 Scheme) Short Answer · 1 mark 40 The preferred first-line pharmacologic treatment for open-angle glaucoma is: 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ (Case) · 1 mark 41 Used in treatment of acute congestive glaucoma 2018 February (2010 Scheme) Short Answer · 1 mark 42 Why is benzhexol used in the treatment of drug induced Parkinsonism. 2018 February (2010 Scheme) Short Answer · 1 mark 43 Drugs used in Myasthenia gravis 2013 April (2010 Scheme) Short Answer · 1 mark 44 Trihexyphenidyl in drug induced extrapyramidal syndrome 2021 May (Supplementary) (2010 Scheme) Short Answer · 1 mark 45 The Vasicoselective anticholinergic used in urinary frequency, urgency, and dysuria is 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ · 1 mark 46 Bronchodilators (of two different groups) 2013 September (Supplementary) (2010 Scheme) Short Answer · 1 mark 47 Vesico-selective anticholinergics 2020 February (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 48 Levodopa in Drug induced parkinsonism.
Name the following (Two examples for each): (5x1=5) 2025 March (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 49 Ketoconazole in fungal meningitis
Name the following (Two examples for each) (5x1=5) 2019 July (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 50 Drugs for open angle glaucoma 2019 July (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 51 Neostigmine in glaucoma management
Name the following (Two examples for each): (5x1=5) 2020 February (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 52 Anticholinesterases 2024 August (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 53 Neostigmine in atropine poisoning 2022 May (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 54 Neostigmine for Atropine poisoning 2022 October (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 55 Phenylephrine for refraction testing. 2024 June (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 56 Drugs used to treat Alzheimer’s disease. 2024 June (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 57 Pyridostigmine for the diagnosis of Myasthenia gravis. 2022 February (2019 Scheme) Short Answer · 0.2 marks 58 Drugs used to treat Organophosphorus poisoning 2022 February (2019 Scheme) Short Answer · 0.2 marks 59 Vasicoselective anticholinergics. 2023 January (Supplementary) (2019 Scheme) Short Answer · 0.2 marks 60 Benzhexol in chlorpromazine induced Parkinsonism
Name the following (Two examples for each): (8x1=8) 2023 January (Supplementary) (2019 Scheme) Short Answer · 0.2 marks